InventisBio (SH:688382) Xin Lang Cai Jing·2026-01-22 05:31Core Viewpoint - Yifang Biotechnology's stock has experienced a decline of 5.01% on January 22, with a total market value of 15.124 billion yuan and a cumulative drop of 8.66% over three consecutive days [1] Group 1: Company Overview - Yifang Biotechnology (Shanghai) Co., Ltd. was established on January 11, 2013, and went public on July 25, 2022 [1] - The company's main business involves the research, production, and sales of innovative drugs, with 100% of its revenue derived from technology licensing and cooperation [1] Group 2: Shareholder Information - Among the top ten circulating shareholders, a fund under China Europe Fund, the China Europe Medical Health Mixed A (003095), reduced its holdings by 944,700 shares, now holding 8.1477 million shares, which is 1.95% of the circulating shares [2] - The estimated floating loss for the fund today is approximately 11.2438 million yuan, with a total floating loss of 21.2655 million yuan over the three-day decline [2] Group 3: Fund Performance - The China Europe Medical Health Mixed A (003095) fund has a total asset size of 13.843 billion yuan, with a year-to-date return of 4.64% and a one-year return of 21.99% [2] - The fund manager, Ge Lan, has a tenure of 10 years and 362 days, with the best return during this period being 106.94% [3] Group 4: Fund Holdings - The China Europe National Index 2000 Enhanced A (018663) fund holds 10,000 shares of Yifang Biotechnology, unchanged from the previous period, representing 0.29% of the fund's net value [4] - The estimated floating loss for this fund today is about 13,800 yuan, with a total floating loss of 26,100 yuan over the three-day decline [4] Group 5: Additional Fund Manager Information - The fund manager for China Europe National Index 2000 Enhanced A (018663), Qian Yating, has a tenure of 4 years and 82 days, with the best return during this period being 85.19% [5]